A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 933 participants.
Also called NCT03214380
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 933 participants
- Sponsor
- Registry
-
NCT03214380 -
2015-005357-12
-
- Other papers using this trial's data
- Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Czechia, Germany, Hungary, India, Italy, Japan, Mexico, Puerto Rico, Russia, Slovakia, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03214380. Randomized; double masking; primary purpose treatment. Start 2017-07-14 (actual); primary completion 2018-08-14 (actual). Results posted on 2020-03-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
- Acronym
- PRONTO-T2D
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LY900014
- Intervention (Drug)
- Insulin Lispro
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Insulin Degludec
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03214380- Content hash
431ae26f974223c4d820454d323f0457e9e2a466d981d2570478bfebc07a0813